The face, hands and arms are often affected and, depending on the severity, patients suffer enormously: But a very promising biological agent has now been approved for atopic dermatitis.
The German Dermatological Society (DDG) states that two million children and 2.5 million adults in Germany suffer from neurodermatitis every year.
And the numbers could go up, according to dermatologists.
Doctors suspect that not only hereditary predisposition, but also unfavorable environmental influences such as pollution in the air or a diet with highly processed foods * promote neurodermatitis.
Lightly dosed cortisone preparations, antipruritic drugs or anti-germ agents are often used against a light form.
In severe cases, drugs that inhibit the immune system are often used.
But a new preparation promises a far more targeted and therefore gentler therapy
.
Scaly and itchy areas of skin as well as inflammatory skin changes (eczema) speak for neurodermatitis - a skin disease that can also put a heavy strain on the psyche.
While there are different treatment options, many drugs have side effects.
A newly developed preparation that has now been approved promises quick success in the treatment of neurodermatitis - at the same time, it should be very gentle
.
We are
talking about the
first approved biological drug dupilumab for the therapy of neurodermatitis
.
It is a preparation that specifically inhibits the processes in the body that are responsible for the development of skin changes.
Biologics are biotechnologically produced protein substances that are directed against certain inflammatory messenger substances in the body or directly against immune cells - and thus can also alleviate the suffering of neurodermatitis.
Also read
: Model “sheds” her skin every two weeks: career despite fish scale disease?
Less itching and better skin with dupilumab
“With this first biologic we are actually dealing with a quantum leap in the care of the disease,” summarizes Professor Matthias Augustin, specialist in skin and venereal diseases at the University Clinic Hamburg-Eppendorf (UKE) and director of the Institute for Health Services Research dermatology and nursing professions.
So far, no drug can be used for long-term care in the field of drug treatment for severely affected patients, which has changed with dupilumab: “We are finally where we have been for 15 years with the other common skin disease, psoriasis.
There are now 13 different medications,
we are only just starting with neurodermatitis, but we are just as hopeful,
”said Augustin.
The new biological drug dupilumab
More and more neurodermatitis patients are being administered - with positive results, says Augustin: “
The effectiveness of dupilumab has been researched in several clinical studies.
In everyday and practice conditions, we see that at least 60 to 70 percent of our patients respond very well to them.
The markers are: reduction of itching, improvement of the skin's appearance, being able to sleep better, ”as ntv quotes him.
(jg)
*
Merkur.de is part of the nationwide Ippen-Digital editors network
.
More sources: www.allergieinformationsdienst.de;
www.rheuma-liga.de
Read more
: Hives: If the skin burns like fire, definitely don't make this mistake.
Wellness vacation with natural remedies
Wellness vacation with natural remedies
